AUGMENT: Lenalidomide plus Rituximab in R/R Follicular Lymphoma

Opinion
Video

Experts review data updates from the AUGMENT trial and discuss potential clinical implications of these study findings.

Recent Videos
A panel of 3 experts on CML
Related Content
The FDA has set a Prescription Drug User Fee Act date in the first quarter of 2025 for the potential approval of acalabrutinib in previously untreated MCL.

Acalabrutinib Earns FDA Priority Review in Untreated Mantle Cell Lymphoma

Russ Conroy
October 3rd 2024
Article

The FDA has set a Prescription Drug User Fee Act date in the first quarter of 2025 for the potential approval of acalabrutinib in previously untreated MCL.

Leaders from the lymphoma space highlight the importance of mentorship in establishing their careers and impart advice to women looking to advance theirs.

Overcoming Physical and Social Barriers in the Lymphoma Field

Julie M. Vose, MD, MBA;Avyakta Kallam, MD
July 15th 2024
Podcast

Leaders from the lymphoma space highlight the importance of mentorship in establishing their careers and impart advice to women looking to advance theirs.

Complete responses were observed in a small cohort of patients with DLBCL who have previously received autologous CAR T-cell therapy.

Azer-Cel Achieves Complete Responses in Relapsed/Refractory DLBCL

Harrison Widelitz
September 18th 2024
Article

Complete responses were observed in a small cohort of patients with DLBCL who have previously received autologous CAR T-cell therapy.

Bispecific antibodies including epcoritamab have “a lot of potential for upward mobility” in lymphoma, according to Tycel Phillips, MD.

Epcoritamab Approval Expands Bispecific Use in Follicular Lymphoma

Tycel Phillips, MD
July 8th 2024
Podcast

Bispecific antibodies including epcoritamab have “a lot of potential for upward mobility” in lymphoma, according to Tycel Phillips, MD.

Efficacy, safety, time, and cost were all factors assessed between subcutaneous and intravenous rituximab for patients with non-Hodgkin lymphoma.

Data Support Increased Subcutaneous Rituximab Use in Non-Hodgkin Lymphoma

Ariana Pelosci
September 6th 2024
Article

Efficacy, safety, time, and cost were all factors assessed between subcutaneous and intravenous rituximab for patients with non-Hodgkin lymphoma.

The European Commission’s decision represents the first regulatory approval of odronextamab for patients with follicular lymphoma or DLBCL.

Odronextamab Earns European Approval in R/R Follicular Lymphoma, DLBCL

Russ Conroy
August 26th 2024
Article

The European Commission’s decision represents the first regulatory approval of odronextamab for patients with follicular lymphoma or DLBCL.